Our data suggest that interventions designed to modulate epithelial responses to Th17 signals, limit viral replication, or dampen synergistic cytokine amplification (e.g., TNF-α or IL-1β blockade) may hold promise for reducing exacerbation severity in non-T2 asthma. The gene discussed is IL1B; the disease is asthma.